Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma

BMC Cancer

Technical Advance

Hamid Reza Sima¹  Samaneh Boroumand-Noughabi²  Kamran Ghaffarzadehgan³  Hamid Reza Raziee⁴  Mohammad Taghi Rajabi-Mashhadi⁵  Amir Abbas Azarian⁶  Omeed Moaven⁷  Mojtaba Mashhadinejad⁷  Hanieh Hosseinnezhad⁸  Mostafa Jafarzadeh⁸  Jalil Tavakkol-Afshari⁹ 

[1] Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran;Department of Pathology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran;Gastric Cancer Research Group, Mashhad University of Medical Sciences, Mashhad, Iran;Department of Pathology, Mashhad University Cancer Research Center, Omid Oncology Hospital, Mashhad University of Medical Sciences, Mashhad, Iran;Department of Radiation Oncology, Mashhad University Cancer Research Center, Omid Oncology Hospital, Mashhad University of Medical Sciences, Mashhad, Iran;Department of surgery, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran;Division of statistics, vice chancellery for research, Mashhad University of Medical Sciences, Mashhad, Iran;Gastric Cancer Research Group, Mashhad University of Medical Sciences, Mashhad, Iran;Gastric Cancer Research Group, Mashhad University of Medical Sciences, Mashhad, Iran;Young Researchers' Club, Medical School of Islamic Azad University of Mashhad, Mashhad, Iran;Immunogenetic and Cell Culture Department, Immunology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran;

关键词: Gastric Cancer;    Pylorus Infection;    Gastric Cancer Patient;    Gastric Adenocarcinoma;    Intestinal Metaplasia;   

DOI  :  10.1186/1471-2407-10-275

 received in 2009-09-07, accepted in 2010-06-10,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundFas (Apo-1/CD95) and its specific ligand (FasL) are key elements in apoptosis. They have been studied in different malignancies but there are few published studies about the soluble forms of these markers (i.e. sFas/sFasL) in gastric cancer. We have compared the serum levels of sFas/sFasL in gastric adenocarcinoma patients and cases with pre-neoplastic lesions as potential markers for early diagnosis, and investigated their relation with clinicopathological characteristics.MethodsFifty-nine newly-diagnosed cases of gastric adenocarcinoma who had undergone gastrectomy, along with 62 endoscopically- and histologically-confirmed non-cancer individuals were enrolled in this study. sFas/sFasL serum levels were detected by Enzyme Linked Immunosurbent Assay.ResultsMean serum sFas level was significantly higher in gastric cancer patients than in control group (305.97 ± 63.71 (pg/ml) vs. 92.98 ± 4.95 (pg/ml), P < 0.001); while the mean serum level of sFasL was lower in patients with gastric adenocarcinoma (0.138 ± 0.04 (pg/ml) vs. 0.150 ± 0.02 (pg/ml), P < 0.001). Mean serum levels of sFas/sFasL were significantly different in both intestinal/diffuse and cardiac/non-cardiac subtypes when compared to the control group (P < 0.001). There was an increase in the serum level of sFas from the first steps of pre-neoplastic lesions to gastric adenocarcinoma (P < 0.001). Patients who had no lymph node involvement (N0 ) showed significantly higher serum levels of sFas compared to others (P = 0.044).ConclusionsProduction of sFas may play a critical role in the carcinogenesis of intestinal-type gastric cancer. sFas serum level may serve as a non-invasive tool for early diagnosis of gastric cancer.

【 授权许可】

Unknown   
© Boroumand-Noughabi et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.